Why do cancer treatment options (chemotherapies + radiations) have outcome failure rates of 90% (+/-5) for solid tumors?
Despite seven decades of basic science, epidemiological and animal studies or clinical trials on cancer research and therapy, why cancer treatment options (chemotherapies + radiations) have outcome failure rates of 90% (+/-5) for solid tumors, according to governmental and private organizations. Please select your answer among the followings:
1. Need more research funding for epidemiological studies and experimental models of tumors and clinical trials.
2. Cancer is too many (100, 200 or 1000) diseases according to reports by NCI and scientific publications.
3. Cancer immunobiology is very complicated.
4. Lack of sufficient identification of genetic mutations that are present in site-specific cancer microenvironments to develop more effective therapy.
5. Lack of direct evidence between stimuli- (immune triggers)-induced time-course kinetics of immune response alterations toward multistep carcinogenesis.
6. Need effective targeted therapy, precision or personalized medicine and immunotherapy.
7. I can’t answer that.
Please explain your answer.
Drug Discovery
Mechanisms of action
Medicine
Oncology
Reham L. Aggour
6. Need effective targeted therapy, precision or personalized medicine and immunotherapy.
Dr. Ronald B. Brown
Need more research funding for epidemiological studies and experimental models of tumors and clinical trials.
Epidemiology studies the cause and prevention of diseases like cancer, while medical research concentrates more on diagnosis and treatment. Cancer is not caused by lack of medical treatments! Symptomatic treatments do not remove underlying causes. The medical model is insufficient to help people prevent or recover from cancer. This is why so many cancer therapy trials have failed and will continue to fail.
My research focus is on the nutritional epidemiology of cancer. A promising discovery that requires clinical testing on cancer patients is a low-phosphate diet, already in use for chronic kidney disease patients. Excessive phosphate in tissue drives tumor growth.
Please see my Google Scholar profile for my publications on cancer and other diseases:
Ronald B. Brown, Ph.D. - Google Scholar
Epidemiology studies the cause and prevention of diseases like cancer, while medical research concentrates more on diagnosis and treatment. Cancer is not caused by lack of medical treatments! Symptomatic treatments do not remove underlying causes. The medical model is insufficient to help people prevent or recover from cancer. This is why so many cancer therapy trials have failed and will continue to fail.
My research focus is on the nutritional epidemiology of cancer. A promising discovery that requires clinical testing on cancer patients is a low-phosphate diet, already in use for chronic kidney disease patients. Excessive phosphate in tissue drives tumor growth.
Please see my Google Scholar profile for my publications on cancer and other diseases:
Ronald B. Brown, Ph.D. - Google Scholar
Richa Radonc
Lack of sufficient identification of genetic mutations that are present in site-specific cancer microenvironments to develop more effective therapy.
I agree there has been recent developments in basic science studies for cancer, but these are limited to certain populations of the world and in limited sites of cancer.
The survival rate of same disease in similar stage and with same treatment also differs across the world.
The reason could be the different genetic make up of the individual patient and in how that person metabolises the given drug. Other reasons could be different etiologies of the same disease, different patterns of nutrition and comorbidities across the globe.
So, I think we need to do more site, population and region specific studies and be more individualised in our treatment.
I agree there has been recent developments in basic science studies for cancer, but these are limited to certain populations of the world and in limited sites of cancer.
The survival rate of same disease in similar stage and with same treatment also differs across the world.
The reason could be the different genetic make up of the individual patient and in how that person metabolises the given drug. Other reasons could be different etiologies of the same disease, different patterns of nutrition and comorbidities across the globe.
So, I think we need to do more site, population and region specific studies and be more individualised in our treatment.
Adel S. Al-Zubairi